000			04582nam a22005055i 4500
001			u370595
003			SIRSI
005			20160812080041.0
007			cr nn 008mamaa
008			110627s2011 xxk| s |||| 0|eng d
020			_a9780857296061 _9978-0-85729-606-1
040			_cMX-MeUAM
050		4	_aRC86-88.9
082	0	4	_a616.028 _223
100	1		_aKane-Gill, Sandra. _eeditor.
245	1	0	_aHigh-Risk IV Medications in Special Patient Populations _h[recurso electrónico] / _cedited by Sandra Kane-Gill, Joseph Dasta.
264		1	_aLondon : _bSpringer London : _bImprint: Springer, _c2011.
300			_aX, 160 p. _bonline resource.
336			_atext _btxt _2rdacontent
337			_acomputer _bc _2rdamedia
338			_aonline resource _bcr _2rdacarrier
347			_atext file _bPDF _2rda
505	0		_aAnesthetic agents (general, inhaled, intravenous) -- Propofol, ketamine, etc -- Anti-infectives -- aminoglycosides, vancomycin, drotrecogin, amphotericin products -- inhaled agents -- Anticoagulants agents -- unfractionated heparin, low molecular weight heparins, fondaparinux, lepirudin, argatroban, bivalrudin, abciximab, eptifibatide, tirofiban -- Thrombolytics –reteplase, tenecteplase, streptokinase, urokinase, alteplase -- Cardiac Drugs -- Adrenergic agents -- dopamine, dobutamine, vasopressin, , nitroglycerin, nitroprusside epinephrine, norepinepherine, phenylepherine -- Adrenergic antagonists -- Propranolol, diltiazem, verapamil, esmolol, labetalol, clevidipine -- Antidyrrhthmics -- amiodarone, lidocaine, procainamide -- Inotropic agents -- milrinone, amrinone, isoproterenol, niseritide, digoxin -- Prostanoids -- Epoprostenol, iloprost, treprostenil -- Electrolytes -- Potassium, magnesium, sodium chloride (hypertonic), cardioplegic solutions -- Hypoglycemics -- Insulin and oral agents -- Neuromuscular blocking agents -- vecuronium, rocuronium, cisatracurium, atracurium, succinylcholine -- Opioids (IV, oral) -- Remifentanyl, fentanyl , morphine, hydromorphone, meperidine -- Sedatives (IV, oral and transdermal) -- lorazepam, midazolam, diazepam, propofol, dexmedetomidine -- Information for Each Drug -- Propofol -- Normal -- Obese -- Renal Dysfunction -- CrCL -- Dialysis (HD, CRRT) -- Liver Dysfunction -- Recommendations for Safe Use.
520			_aCritically ill patients are at risk for a higher frequency and severity of adverse drug events (ADEs), and special patient populations of the critically ill – requiring for instance individualized dosing due to non-average weight, hepatic or renal dysfunction, extracorporeal circulation devices, advanced age, pharmacogenetic alterations, hemodynamic instability, or therapeutic hypothermia – are particularly challenging. A contributing factor to this is the use of high-risk medications with many administered intravenously (IV). Hypervigilant monitoring of high-risk medications is still essential to prevent patient harm, especially in populations that have dosing challenges, hence, regulatory bodies internationally require active institutional surveillance of high-risk medications. These dosing challenges are a great safety concern, since there is considerable risk of unwanted adverse drug events from overdosing or therapeutic inefficacy from underdosing. High-Risk IV Medications in Special Patient Populations reviews high-risk IV medication dosage considerations for special patient populations and discusses the safety concerns of these medications to aid the clinician in cautious monitoring.  The authors provide clinicians with tools to minimize adverse drug events with IV high-risk medications, while maximizing the beneficial clinical effects of these drugs, thus making this book essential reading for all involved with the care of critically ill patients.
650		0	_aMedicine.
650		0	_aPharmacy.
650		0	_aAnesthesiology.
650		0	_aEmergency medicine.
650		0	_aCritical care medicine.
650		0	_aInternal medicine.
650	1	4	_aMedicine & Public Health.
650	2	4	_aIntensive / Critical Care Medicine.
650	2	4	_aInternal Medicine.
650	2	4	_aEmergency Medicine.
650	2	4	_aAnesthesiology.
650	2	4	_aPharmacy.
700	1		_aDasta, Joseph. _eeditor.
710	2		_aSpringerLink (Online service)
773	0		_tSpringer eBooks
776	0	8	_iPrinted edition: _z9780857296054
856	4	0	_zLibro electrónico _uhttp://148.231.10.114:2048/login?url=http://link.springer.com/book/10.1007/978-0-85729-606-1
596			_a19
942			_cLIBRO_ELEC
999			_c198475 _d198475